Comparison between tazarotene 0.05 percent gel and adapalene 0.1 percent gel in acne patients.

Efficacy of Tazarotene 0.05 percent gel vs Adapalene 0.1 percent gel in treatment of acne vulgaris A randomised case controlled trial

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/06/069345

Enrollment

150

Registered

2024-06-21

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L700- Acne vulgaris

Interventions

Intervention1: Tazarotene: Tazarotene Dose- 0.05% gel ROA- topical Frequency- once a day Duration of Treatment - 12 weeks Control Intervention1: Adapelene: Dose- 0.1% gel ROA- topical Frequency- onc

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients irrespective of gender. 2) Patients with age >12 – 35 years. 3) Patients willing to participate. 4) Patients with acne grade: I, II, III.

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity or allergic reaction to retinoids 2. Patients with a history of photosensitivity. 3. Females who are pregnant, lactating mothers and married women planning for pregnancy. 4. Patient with photo aggravated disorders.

Design outcomes

Primary

Measure	Time frame
To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, and the side effects that arise with the usage of 0.05% tazarotene and 0.1% adapalene.Timepoint: 1 year 2 months	—

Secondary

Measure	Time frame
Total clearance of lesions, improvement in numbers of counts of comedones, papules, pustules, & nodules, improvement in global acne scoring, side effects i.e. dryness, erythema, itching, & flare-up of acne will be studied. To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, & the side effects that arise with the usage of 0.05% tazarotene & 0.1% adapalene.Timepoint: 12 weeks;treatment wherein oral medication need not be given or are contraindicated.Timepoint: 8 weeks	—

Measure

Time frame

Total clearance of lesions, improvement in numbers of counts of comedones, papules, pustules, & nodules, improvement in global acne scoring, side effects i.e. dryness, erythema, itching, & flare-up of acne will be studied. To observe the improvement in the acne of patients based on Global acne scoring systems, keeping a note of the decrease in the number of counts of lesions with every follow-up visit or clearance of lesions, subjective patient improvement scoring, & the side effects that arise with the usage of 0.05% tazarotene & 0.1% adapalene.Timepoint: 12 weeks;treatment wherein oral medication need not be given or are contraindicated.Timepoint: 8 weeks

—

Countries

India

Contacts

Public ContactSharwari Jaiswal

Datta Meghe Institute of Higher Education and Research

drsugat09@gmail.com9096446172

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026